Mei Feng

Shanghai, 201203, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Targeting BCL9/BCL9L enhances CD4+ T cell-mediated Th1 antitumor immunity through activation of STAT1/STAT4 signaling.

Targeting BCL9/BCL9L enhances CD4+ T cell-mediated Th1 antitumor immunity through activation of STAT1/STAT4 signaling.

Journal: Acta pharmacologica Sinica

Published: December 21, 2025

BCL9 inhibition promotes fibroblast lipogenesis by regulating macrophage-fibroblast interactions to attenuate pulmonary fibrosis.

BCL9 inhibition promotes fibroblast lipogenesis by regulating macrophage-fibroblast interactions to attenuate pulmonary fibrosis.

Journal: Signal transduction and targeted therapy

Published: September 16, 2025

Single-cell mapping of peripheral blood mononuclear cells reveals key transcriptomic changes favoring coronary artery lesion in IVIG-resistant Kawasaki disease.

Single-cell mapping of peripheral blood mononuclear cells reveals key transcriptomic changes favoring coronary artery lesion in IVIG-resistant Kawasaki disease.

Journal: Heliyon

Published: March 23, 2024

Tumor-infiltrated activated B cells suppress liver metastasis of colorectal cancers.

Tumor-infiltrated activated B cells suppress liver metastasis of colorectal cancers.

Journal: Cell reports

Published: March 09, 2022

Inhibition of BCL9 Modulates the Cellular Landscape of Tumor-Associated Macrophages in the Tumor Immune Microenvironment of Colorectal Cancer.

Inhibition of BCL9 Modulates the Cellular Landscape of Tumor-Associated Macrophages in the Tumor Immune Microenvironment of Colorectal Cancer.

Journal: Frontiers in pharmacology

Published: May 22, 2021

RORγt agonist synergizes with CTLA-4 antibody to inhibit tumor growth through inhibition of Treg cells via TGF-β signaling in cancer.

RORγt agonist synergizes with CTLA-4 antibody to inhibit tumor growth through inhibition of Treg cells via TGF-β signaling in cancer.

Journal: Pharmacological research

Published: April 18, 2021

BCL9 regulates CD226 and CD96 checkpoints in CD8+ T cells to improve PD-1 response in cancer.

BCL9 regulates CD226 and CD96 checkpoints in CD8+ T cells to improve PD-1 response in cancer.

Journal: Signal transduction and targeted therapy

Published: December 03, 2020

Bcl9 Depletion Modulates Endothelial Cell in Tumor Immune Microenvironment in Colorectal Cancer Tumor.

Bcl9 Depletion Modulates Endothelial Cell in Tumor Immune Microenvironment in Colorectal Cancer Tumor.

Journal: Frontiers in oncology

Published: September 07, 2020

Pharmacological Inhibition and Genetic Knockdown of BCL9 Modulate the Cellular Landscape of Cancer-Associated Fibroblasts in the Tumor-Immune Microenvironment of Colorectal Cancer.

Pharmacological Inhibition and Genetic Knockdown of BCL9 Modulate the Cellular Landscape of Cancer-Associated Fibroblasts in the Tumor-Immune Microenvironment of Colorectal Cancer.

Journal: Frontiers in oncology

Published: September 07, 2020

BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer.

BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer.

Journal: Oncogene

Published: August 11, 2020

T-cell-based immunotherapy in colorectal cancer.

T-cell-based immunotherapy in colorectal cancer.

Journal: Cancer letters

Published: June 12, 2020

Wnt Signaling in Inflammation in Tissue Repair and Regeneration.

Wnt Signaling in Inflammation in Tissue Repair and Regeneration.

Journal: Current protein & peptide science

Published: December 17, 2018

Showing 1-12 of 12

Last Updated: 09/26/2026